<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title> Sample Size and Power for Counts and Rates</title>

<script src="site_libs/header-attrs-2.29/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cerulean.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<link href="site_libs/pagedtable-1.1/css/pagedtable.css" rel="stylesheet" />
<script src="site_libs/pagedtable-1.1/js/pagedtable.js"></script>
<link href="site_libs/font-awesome-6.5.2/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Zehui Bai</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="index.html">
    <span class="fa fa-home"></span>
     
    Home
  </a>
</li>
<li>
  <a href="02-Clinical_Experience.html">
    <span class="fa fa-user"></span>
     
    Clinical Experience
  </a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-sliders"></span>
     
    Sample Size
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="03-SSC-Everything-to-Know-About-Sample-Size-Determination.html">Everything to Know About Sample Size Determination</a>
    </li>
    <li>
      <a href="03-SSC-Choosing-the-Effect-Size-for-Sample-Size-Calculations.html">Choosing the Effect Size</a>
    </li>
    <li>
      <a href="03-SSC-Biosimilar-Trials.html">Statistical Considerations for the Design and Analysis of Biosimilar Trials</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-and-Power-for-Non-Parametric-Analysis.html">Sample Size and Power for Non-Parametric Analysis</a>
    </li>
    <li>
      <a href="03-SSC-Power-for-Complex-Hypotheses.html">Power for Complex Hypotheses</a>
    </li>
    <li>
      <a href="03-SSC-Alternatives-to-Power.html">Bayesian methods - Alternatives to Power</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-for-Pilot-Studies.html">Sample Size for Pilot Studies</a>
    </li>
    <li>
      <a href="03-SSC-Case-Continuous-Endpoint.html">Sample Size Determination for Continuous Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Categorical-Endpoint.html">Sample Size Determination for Categorical Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-Determination-for-Counts-and-Rates.html">Sample Size Determination for Counts and Rates</a>
    </li>
    <li>
      <a href="03-SSC-Case-Survival-Endpoint.html">Sample Size Determination for Survival Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Repeated-Measures.html">Sample Size Determination for Repeated Measures</a>
    </li>
    <li>
      <a href="03-SSC-IA-Sequential-Design.html">Statistical Considerations for Group Sequential Design</a>
    </li>
    <li>
      <a href="03-SSC-IA-Adaptive-Design.html">Statistical Considerations for Adaptive Design</a>
    </li>
    <li>
      <a href="03-SSC-Multiple-Test.html">Sample Size for Multiple Test</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-pencil-square-o"></span>
     
    Study Design
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="04-Design-Estimands-Framework.html">Estimands Framework</a>
    </li>
    <li>
      <a href="04-Design-Estimands-Practice.html">Estimands and Sensitivity Analyses</a>
    </li>
    <li>
      <a href="04-Design-Phase-I-Trials---Design-Considerations.html">Phase I Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-II-Trials---Design-Considerations.html">Phase II Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-III-Trials---Design-Considerations.html">Phase III Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-IV-Trials---Design-Considerations.html">Phase IV Trials - Design Considerations for Post Marketing Surveillance</a>
    </li>
    <li>
      <a href="04-Design-Complex-Sequential-Trials.html">Complex Sequential Analysis Trials</a>
    </li>
    <li>
      <a href="04-Design-Adaptive-Clinical-Trials.html">Adaptive Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Bayesian-Clinical-Trials.html">Bayesian Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Dose-Escalation-and-Stratification-Designs.html">Dose Escalation and Stratification Designs in Early Oncology Development</a>
    </li>
    <li>
      <a href="04-Design-Single-Arm-Clinical-Trials.html">Single Arm Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Diagnostic-Study-Design-and-Evaluation.html">Diagnostic Study-Design and Evaluation</a>
    </li>
    <li>
      <a href="04-Design-Diagnostic-Study-MRMC.html">Diagnostic Study-Multireader Multicase (MRMC)</a>
    </li>
    <li>
      <a href="04-Design-Hierarchical-composite-endpoints.html">Hierarchical Composite Endpoints</a>
    </li>
    <li>
      <a href="04-Design-Externally-Controlled-Trials.html">Considerations for the Design and Conduct of Externally Controlled Trials</a>
    </li>
    <li>
      <a href="04-Design-Noninferiority-Trials.html">Noninferiority Trials</a>
    </li>
    <li>
      <a href="04-Design-Bioequivalence-and-Biosimilar-Trials.html">Bioequivalence and Biosimilar Trials</a>
    </li>
    <li>
      <a href="04-Design-Exploring-Survival-Analysis-Designs-for-Clinical-Trials.html">Exploring Survival Analysis Designs for Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Projecting-How-Long-Your-Trial-Will-Take.html">Projecting How Long Your Trial Will Take</a>
    </li>
    <li>
      <a href="04-Design-Regulatory-Submission.html">Regulatory Submission from Stats Perspective</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-line-chart"></span>
     
    Data Visualization
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="05-Plot-Adverse-Event.html">Adverse Event Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Laboratory-Data.html">Laboratory Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Time-To-Event.html">Time to Event Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-PRO-Data.html">Patient Reported Outcome Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-SSC-and-Power-Calculation.html">Sample Size and Power Calculations Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Correlation.html">Correlation Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Model-Table.html">Clinical Data and Model visualization</a>
    </li>
    <li>
      <a href="05-Plot-ScatterPlot.html">Scatter and Line Plot</a>
    </li>
    <li>
      <a href="05-Plot-BarPlot.html">Bar Chart</a>
    </li>
    <li>
      <a href="05-Plot-PieChart.html">Pie Chart</a>
    </li>
    <li>
      <a href="05-Plot-BoxPlot.html">Box Plot</a>
    </li>
    <li>
      <a href="05-Plot-Histogram.html">Histogram</a>
    </li>
    <li>
      <a href="05-Plot-Forest-Plot.html">Forest Plot</a>
    </li>
    <li>
      <a href="05-Plot-Flow-Chart.html">Flow Chart</a>
    </li>
    <li>
      <a href="05-Plot-Some-Interesting.html">Some Interesting Plots</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-calculator"></span>
     
    Statistical Analysis
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="06-Analysis-Linear-Regression.html">Linear Regression</a>
    </li>
    <li>
      <a href="06-Analysis-Logistic-Regression.html">Logistic Regression</a>
    </li>
    <li>
      <a href="06-Analysis-Mixed-Model.html">Mixed Model</a>
    </li>
    <li>
      <a href="06-Analysis-MMRM.html">Mixed Model Repeated Measures</a>
    </li>
    <li>
      <a href="06-Analysis-GEE.html">Generalized Estimating Equation</a>
    </li>
    <li>
      <a href="06-Analysis-ANOVA.html">Analysis of Variance</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Analysis.html">Survival Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Competing-Risk.html">Survival Analysis - Competing Risk</a>
    </li>
    <li>
      <a href="06-Analysis-Missing-Data.html">Missing Data Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-MI-Implementation.html">Multiple Imputation Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-SSD.html">Safety Signal Detection and Evaluation</a>
    </li>
    <li>
      <a href="06-Analysis-Meta-Analysis.html">Meta Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-PK-and-PD.html">PK and PD Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Time-Series-Analysis.html">Time Series Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-SEM.html">Structural Equation Modeling</a>
    </li>
    <li>
      <a href="06-Analysis-Factor-Analysis.html">Factor Analysis</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-bar-chart"></span>
     
    Machine Learning
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="07-ML-Bayesian-Theory.html">Bayesian Theory</a>
    </li>
    <li>
      <a href="07-ML-Bayesian-Analysis.html">Bayesian Analysis</a>
    </li>
    <li>
      <a href="07-ML-Regularization-Penalized-Regression.html">Regularization Penalized Regression</a>
    </li>
    <li>
      <a href="07-ML-Loss-Regression.html">Loss Functions in Machine Learning</a>
    </li>
    <li>
      <a href="07-ML-PCA.html">Principal Component Analysis</a>
    </li>
    <li>
      <a href="07-ML-KNN.html">K-Nearest Neighbors</a>
    </li>
    <li>
      <a href="07-ML-SVM.html">Support Vector Machine</a>
    </li>
    <li>
      <a href="07-ML-Tree-Models.html">Tree Models</a>
    </li>
    <li>
      <a href="07-ML-LDA.html">Linear Discriminant Analysis</a>
    </li>
    <li>
      <a href="07-ML-Cluster-Analysis.html">Cluster Analysis</a>
    </li>
    <li>
      <a href="07-ML-Neural-Networks.html">Neural Network</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="08-CV.html">
    <span class="fa fa-file-pdf-o"></span>
     
    CV
  </a>
</li>
<li>
  <a href="mailto:zehuibai@outlook.com">
    <span class="fa fa-envelope-o"></span>
     
    Contact me
  </a>
</li>
<li>
  <a href="https://github.com/Zehuibai">
    <span class="fa fa-github"></span>
     
    GitHub
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore"><p><img src="logo.png"
style="width:3in" /><br />
Sample Size and Power for Counts and Rates</p></h1>

</div>


<div id="introduction-to-counts-rates" class="section level1"
number="1">
<h1><span class="header-section-number">1</span> Introduction to Counts
&amp; Rates</h1>
<div id="incidence-rate-and-counts" class="section level2" number="1.1">
<h2><span class="header-section-number">1.1</span> Incidence Rate and
Counts</h2>
<p>In clinical trials and observational studies, endpoints involving
<strong>repeated or recurrent events</strong> are commonly encountered.
Two main approaches to characterize such endpoints are through
<strong>Incidence Rates</strong> and <strong>Counts</strong>.</p>
<hr />
<p><strong>Incidence Rate</strong> is a measure of the frequency with
which a particular event—typically a medical condition or health-related
episode—occurs over a specified unit of time. This metric is
particularly useful when the <strong>time at risk</strong> varies among
individuals.</p>
<ul>
<li><strong>Definition</strong>: Number of events per unit time (e.g.,
per month, per year).</li>
<li><strong>Example Applications</strong>:
<ul>
<li>Frequency of <strong>COPD exacerbations</strong> (Chronic
Obstructive Pulmonary Disease).</li>
<li><strong>Hospital readmissions</strong> within a year.</li>
</ul></li>
</ul>
<p>These rates incorporate a time component, making them useful when
follow-up times differ across subjects or when events are ongoing over
time.</p>
<hr />
<p><strong>Counts</strong></p>
<p><strong>Counts</strong> represent the total number of occurrences of
an outcome within a defined <strong>unit of observation</strong>, but
without necessarily incorporating time as a component.</p>
<ul>
<li><strong>Definition</strong>: Number of times an event happens per
unit (not necessarily time).</li>
<li><strong>Example Applications</strong>:
<ul>
<li>Number of <strong>MRI scans</strong> per subject in multiple
sclerosis trials.</li>
<li>Number of <strong>lesions</strong> or affected areas in a single
diagnostic scan.</li>
</ul></li>
</ul>
<p>Counts are appropriate when the observation period is fixed or
uniform across individuals, or when the interest lies in a static count
rather than a time-based rate.</p>
<hr />
<p><strong>Relationship Between Counts and Rates</strong></p>
<p>While <strong>rates</strong> and <strong>counts</strong> differ in
their inclusion of time as a denominator, <strong>both aim to measure
the frequency or burden of repeated events</strong>. In practice,
<strong>counts can be treated as rates</strong> by setting the time unit
<span class="math inline">\(t = 1\)</span>, making the rate
interpretation mathematically equivalent to a count per unit.</p>
<blockquote>
<p><strong>Conceptually</strong>:<br />
- Rates = events per unit time<br />
- Counts = events per unit X (e.g., per patient, per scan)</p>
<p><strong>Practically</strong>: Analyzed similarly when time is
constant or not a focus.</p>
</blockquote>
</div>
<div id="modeling-strategies-for-analysis" class="section level2"
number="1.2">
<h2><span class="header-section-number">1.2</span> Modeling Strategies
for Analysis</h2>
<p>There are <strong>multiple modeling strategies</strong> available for
analyzing rate and count data. These fall into <strong>two main
categories</strong>:</p>
<ol style="list-style-type: decimal">
<li><strong>Rate Models</strong></li>
</ol>
<p>These models explicitly account for the time at risk and the number
of events per unit time.</p>
<ul>
<li>Examples:
<ul>
<li><strong>Poisson regression</strong></li>
<li><strong>Negative binomial regression</strong> (accounts for
overdispersion)</li>
<li><strong>Andersen-Gill models</strong></li>
</ul></li>
</ul>
<ol start="2" style="list-style-type: decimal">
<li><strong>Survival-based Models</strong></li>
</ol>
<p>These models focus on <strong>time-to-event</strong> data, including
<strong>gap times</strong> between events or cumulative hazard.</p>
<ul>
<li>Examples:
<ul>
<li><strong>Recurrent event survival models</strong></li>
<li><strong>Time to nth event (TT(S)E)</strong> frameworks</li>
</ul></li>
</ul>
<p>These models offer flexibility to estimate different <strong>effect
sizes</strong>, such as: - Event rate - Time between events (gap times)
- Cumulative number of events over time</p>
<hr />
<p><strong>Common Misuses in Practice</strong></p>
<p>Despite the availability of appropriate methods, <strong>recurrent
event data is often misanalyzed using models not designed for such
structure</strong>, leading to loss of information and reduced
efficiency.</p>
<ul>
<li><strong>Typical (but suboptimal) approaches</strong>:
<ul>
<li>Using only the <strong>first event</strong> per subject (Cox
proportional hazards model).</li>
<li>Collapsing the outcome into a <strong>binary endpoint</strong>
(e.g., logistic regression).</li>
<li>Ignoring repeated measures entirely (e.g., simple t-tests).</li>
</ul></li>
</ul>
<p>These approaches effectively <strong>discard valuable
information</strong> on additional events, underutilizing the full
potential of the data.</p>
<hr />
<p><strong>Scope of Current Focus</strong></p>
<p>In this context, the analysis is restricted to <strong>independent
events</strong> and assumes <strong>no informative censoring</strong>
(i.e., dropouts or event loss not related to prognosis).</p>
<ul>
<li>This avoids complexities introduced by within-subject dependence or
censoring mechanisms.</li>
<li><strong>Composite endpoints</strong> and <strong>within-subject
correlation modeling</strong> (e.g., frailty models or random effects)
are acknowledged as critical areas under active statistical research but
are beyond the current focus.</li>
</ul>
</div>
<div id="statistical-methods-for-counts-rates" class="section level2"
number="1.3">
<h2><span class="header-section-number">1.3</span> Statistical Methods
for Counts &amp; Rates</h2>
<table>
<colgroup>
<col width="12%" />
<col width="5%" />
<col width="23%" />
<col width="30%" />
<col width="27%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Method</strong></th>
<th><strong>Model Type</strong></th>
<th><strong>Key Features</strong></th>
<th><strong>Assumptions / Notes</strong></th>
<th><strong>Use Case</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Poisson Model</strong></td>
<td>Rate Model</td>
<td>Mean = Variance; can be extended for overdispersion and zero
inflation</td>
<td>Assumes events occur independently and uniformly over time</td>
<td>Basic count data with equal mean-variance; uniform event risk</td>
</tr>
<tr class="even">
<td><strong>Negative Binomial (NB) Regression</strong></td>
<td>Rate Model</td>
<td>Adds Gamma-distributed random effect per subject (dispersion
parameter)</td>
<td>Handles overdispersion; allows for subject-specific event
variability</td>
<td>Overdispersed count data or when individuals have varying risk</td>
</tr>
<tr class="odd">
<td><strong>Andersen-Gill (AG) Model</strong></td>
<td>Survival Model</td>
<td>Extends Cox model for recurrent events using counting process
formulation</td>
<td>Assumes independent increments; resets risk interval after each
event</td>
<td>Recurrent events with time-varying covariates and no memory</td>
</tr>
<tr class="even">
<td><strong>Prentice, Williams, Peterson (PWP)</strong></td>
<td>Survival Model</td>
<td>Models <strong>gap times</strong> between events; stratified by
event order</td>
<td>Accounts for correlated events and differing baseline hazard per
event number</td>
<td>Dependent events, gap-time modeling, and different risk for 1st,
2nd, … events</td>
</tr>
<tr class="odd">
<td><strong>Wei, Lin, Weissfeld (WLW)</strong></td>
<td>Survival Model</td>
<td>Marginal models for each event; cumulative effect estimation</td>
<td>Assumes independent risk processes across events, which may not hold
in practice</td>
<td>Exploratory analysis with multiple event types or marginal
modeling</td>
</tr>
<tr class="even">
<td><strong>Frailty Models</strong></td>
<td>Survival Model</td>
<td>Adds random effect (frailty) to account for unobserved
heterogeneity</td>
<td>Assumes subject-level shared frailty affecting all event
hazards</td>
<td>When some patients are more susceptible to repeated events</td>
</tr>
<tr class="odd">
<td><strong>Multi-State Models</strong></td>
<td>Survival Model</td>
<td>Tracks transitions across states (e.g., Healthy → Ill →
Recovered)</td>
<td>Requires well-defined states and transition pathways</td>
<td>Disease progression or event history modeling</td>
</tr>
<tr class="even">
<td><strong>GT-UR, TT-R</strong></td>
<td>Survival Model</td>
<td>General transition/time-to-recurrence models</td>
<td>Complex parametric survival modeling of transitions and
recurrence</td>
<td>Advanced analysis of structured recurrent processes</td>
</tr>
<tr class="odd">
<td><strong>Mean Cumulative Function (MCF)</strong></td>
<td>Non-parametric</td>
<td>Estimates E[# Events] over time without strong model
assumptions</td>
<td>Does not adjust for covariates; primarily used for descriptive
summaries</td>
<td>Visualizing burden of events over time; comparing treatment groups
descriptively</td>
</tr>
</tbody>
</table>
<hr />
<p><strong>1. Poisson Models</strong></p>
<ul>
<li><strong>Key Idea</strong>: Assumes the number of events follows a
Poisson distribution.</li>
<li><strong>Assumption</strong>: Mean = Variance (equidispersion).</li>
<li><strong>Extensions</strong>:
<ul>
<li>Handles <strong>overdispersion</strong> (variance &gt; mean) via
quasi-Poisson or Negative Binomial extensions.</li>
<li>Can also be extended to <strong>zero-inflated</strong> models when
there are excessive zeros (no events).</li>
</ul></li>
<li><strong>Use Case</strong>: Basic count data with homogeneous event
risk across individuals.</li>
</ul>
<hr />
<p><strong>2. Negative Binomial (NB) Regression</strong></p>
<ul>
<li><strong>Key Idea</strong>: Generalizes Poisson by adding a
<strong>random effect</strong> to account for overdispersion.</li>
<li><strong>Mechanism</strong>:
<ul>
<li>Assumes the Poisson rate for each subject is drawn from a
<strong>Gamma distribution</strong>.</li>
<li>The <strong>dispersion parameter</strong> captures variability
between subjects.</li>
</ul></li>
<li><strong>Use Case</strong>: Repeated event data with heterogeneous
risk profiles across subjects.</li>
<li><strong>Advantage</strong>: Accommodates extra-Poisson variation,
common in real-world studies.</li>
</ul>
<hr />
<p><strong>3. Andersen-Gill Model</strong></p>
<ul>
<li><strong>Key Idea</strong>: Extension of the <strong>Cox proportional
hazards model</strong> for recurrent events.</li>
<li><strong>Data Structure</strong>: Each event is treated as a new risk
interval (count process approach).</li>
<li><strong>Assumptions</strong>:
<ul>
<li>Time is reset to the beginning of study for each event.</li>
<li>Independent increments (next event hazard is independent of prior
event history).</li>
</ul></li>
<li><strong>Use Case</strong>: Analyzing recurrent events using
<strong>time-to-event</strong> methodology.</li>
<li><strong>Note</strong>: Shares data structure with Poisson/NB (long
format).</li>
</ul>
<hr />
<p><strong>4. Prentice, Williams, Peterson (PWP) Model</strong></p>
<ul>
<li><strong>Key Idea</strong>: Focuses on the <strong>gap time</strong>
(time since last event) for each k-th event.</li>
<li><strong>Stratification</strong>: Stratifies the model by event
order.</li>
<li><strong>Strengths</strong>:
<ul>
<li>Accounts for within-subject <strong>correlation</strong> and
<strong>event dependence</strong>.</li>
<li>Baseline hazard allowed to differ by event order (e.g., different
risk for first vs. second hospitalization).</li>
</ul></li>
<li><strong>Use Case</strong>: Appropriate when <strong>timing between
events</strong> and <strong>prior event history</strong> are
important.</li>
</ul>
<hr />
<p><strong>5. Wei, Lin and Weissfeld (WLW) Model</strong></p>
<ul>
<li><strong>Key Idea</strong>: Models each k-th event
<strong>marginally</strong> as if it were independent.</li>
<li><strong>Approach</strong>:
<ul>
<li>Multiple time-to-event models for each event.</li>
<li>Allows <strong>multiple event types</strong> and cumulative event
modeling.</li>
</ul></li>
<li><strong>Limitation</strong>: May <strong>violate independence
assumptions</strong> in recurrent settings.</li>
<li><strong>Use Case</strong>: Simplified analysis of <strong>multiple
failure times</strong> per subject.</li>
</ul>
<hr />
<p><strong>6. Other Survival-Based Models</strong></p>
<p>These encompass a range of models built for more complex recurrent
event processes:</p>
<ul>
<li><strong>Frailty Models</strong>: Include random effects (frailty) to
account for <strong>subject-specific heterogeneity</strong>.</li>
<li><strong>Multi-State Models</strong>: Model
<strong>transitions</strong> between different states (e.g., healthy →
sick → hospitalized).</li>
<li><strong>GT-UR / TT-R</strong>: General transition or <strong>time to
recurrence</strong> frameworks.</li>
<li><strong>Use Case</strong>: Complex longitudinal event histories,
particularly when <strong>state-dependence</strong> or <strong>recovery
periods</strong> exist.</li>
</ul>
<hr />
<p><strong>7. Mean Cumulative Function (MCF)</strong></p>
<ul>
<li><strong>Key Idea</strong>: A <strong>non-parametric
estimator</strong> for the <strong>expected number of cumulative
events</strong> over time.</li>
<li><strong>Interpretation</strong>: Provides an intuitive picture of
the burden of disease/events.</li>
<li><strong>Use Case</strong>:
<ul>
<li>Visualizing or summarizing the mean number of events over time.</li>
<li>Especially useful in <strong>descriptive analyses</strong> before
choosing a formal model.</li>
</ul></li>
</ul>
</div>
</div>
<div id="sample-size-determination" class="section level1" number="2">
<h1><span class="header-section-number">2</span> Sample Size
Determination</h1>
<div id="introduction" class="section level2" number="2.1">
<h2><span class="header-section-number">2.1</span> Introduction</h2>
<p><strong>Sample Size Determination for Counts and Rates</strong></p>
<p>Sample size calculation for analyses involving rates and counts has
historically been a limiting factor for widespread adoption of more
advanced models in clinical trials. While traditional methods for
simpler endpoints (like proportions or means) are well established, the
development of robust SSD methods for repeated events data—especially
under more realistic assumptions—has only gained traction in recent
years.</p>
<p><strong>Challenges and Concepts</strong></p>
<ol style="list-style-type: decimal">
<li><strong>Lack of Established Methods Historically</strong>
<ul>
<li>Early clinical trials often relied on simpler models (e.g., binary
outcomes or time to first event).</li>
<li>There was a <strong>scarcity of reliable sample size
formulas</strong> for recurrent event analyses, which discouraged their
use despite being statistically more powerful.</li>
</ul></li>
<li><strong>What Constitutes “Sample Size” for Counts/Rates?</strong>
<ul>
<li>Unlike binary outcomes, where “N” usually refers to the number of
subjects, for rates/counts, the effective sample size is defined
differently:
<ul>
<li>Either <strong>total follow-up time</strong> across all subjects
(e.g., measured in person-years)</li>
<li>Or <strong>total number of expected events</strong></li>
</ul></li>
<li>Hence, sample size estimation depends not just on the number of
subjects, but also on:
<ul>
<li>The <strong>duration of follow-up per subject</strong></li>
<li>The <strong>expected event rate per unit time</strong></li>
</ul></li>
</ul></li>
<li><strong>Recent Developments</strong>
<ul>
<li>There has been a notable increase in research and methodological
development to handle:
<ul>
<li><strong>Complex designs</strong> (e.g., dose-finding, crossover
trials, &gt;2 arms)</li>
<li><strong>More flexible models</strong>, such as Negative Binomial and
Andersen-Gill models</li>
<li><strong>Adaptive designs</strong> that adjust based on interim
analyses or information</li>
</ul></li>
</ul></li>
</ol>
</div>
<div id="evolution-of-ssd-methods" class="section level2" number="2.2">
<h2><span class="header-section-number">2.2</span> Evolution of SSD
Methods</h2>
<p><strong>1. Early Methods (1990s)</strong></p>
<ul>
<li><strong>Lehr (1992)</strong>:
<ul>
<li>Developed a basic sample size formula for comparing two Poisson
rates using normal approximations.</li>
<li>The formula:<br />
<span class="math display">\[
n_{\text{group}} = \frac{4}{(\sqrt{\lambda_1} - \sqrt{\lambda_2})^2}
\]</span></li>
<li>This assumes equal follow-up time, equal variance, and
Poisson-distributed counts.</li>
</ul></li>
<li><strong>Signorini (1991)</strong>:
<ul>
<li>Extended SSD for <strong>Poisson regression</strong>, allowing
inclusion of covariates.</li>
</ul></li>
</ul>
<p><strong>2. Mid-Stage Developments (2010s)</strong></p>
<ul>
<li><strong>Zhu &amp; Lakkis (2014)</strong>:
<ul>
<li>Proposed SSD formulas for <strong>Negative Binomial
regression</strong>, addressing overdispersion and allowing for unequal
rates and variances.</li>
<li>Their formula involves estimating log rate ratios and accounts for
power, type I error, and dispersion. <span class="math display">\[
n_0 \geq \left( \frac{z_{1-\alpha/2}\sqrt{V_0} +
z_{1-\beta}\sqrt{V_1}}{\log(r_1/r_0)} \right)^2
\]</span></li>
<li>These developments made it more practical to plan trials involving
overdispersed count data.</li>
</ul></li>
</ul>
<p><strong>3. Modern Methods (Tang, 2015+)</strong></p>
<ul>
<li><strong>Y. Tang’s framework</strong> represents the current frontier
of SSD for recurrent event data:
<ul>
<li>Accounts for <strong>unequal follow-up and accrual
patterns</strong></li>
<li>Handles <strong>heterogeneous dispersion</strong> across treatment
groups</li>
<li>Adjusts for <strong>dropouts</strong>, <strong>missing
data</strong>, and <strong>adaptive designs</strong></li>
<li>Offers <strong>closed-form approximations</strong> and
simulation-based methods for:
<ul>
<li><strong>Group sequential designs</strong></li>
<li><strong>MCP-Mod</strong> (Multiple Comparison Procedures –
Modeling)</li>
</ul></li>
<li>These methods are particularly important for modern drug
development, where:
<ul>
<li>Event rates are uncertain</li>
<li>Variability between patients is high</li>
<li>Trial designs are more flexible or adaptive</li>
</ul></li>
</ul></li>
</ul>
<hr />
<p><strong>Practical Considerations in SSD for Counts &amp;
Rates</strong></p>
<ul>
<li><strong>Assumptions Must Be Clear</strong>:
<ul>
<li>SSD depends heavily on assumptions about:
<ul>
<li>Event rate per group</li>
<li>Variability or dispersion (if overdispersed)</li>
<li>Follow-up length and dropout rates</li>
</ul></li>
<li>Sensitivity analyses are recommended to account for
uncertainty.</li>
</ul></li>
<li><strong>More Sophisticated SSD = Better Power and
Efficiency</strong>:
<ul>
<li>Using accurate SSD methods for rates (rather than collapsing to
binary or time-to-first-event endpoints) improves trial
<strong>power</strong> and <strong>data utilization</strong>.</li>
<li>However, these methods often require more detailed planning,
collaboration between statisticians and clinicians, and computational
resources.</li>
</ul></li>
</ul>
</div>
<div id="example" class="section level2" number="2.3">
<h2><span class="header-section-number">2.3</span> Example</h2>
<div id="example-1-copd-exacerbation-trial" class="section level3"
number="2.3.1">
<h3><span class="header-section-number">2.3.1</span> Example 1: COPD
Exacerbation Trial</h3>
<p>This is a published trial comparing <strong>fluticasone furoate +
vilanterol</strong> to <strong>vilanterol alone</strong> for the
prevention of <strong>COPD exacerbations</strong>.</p>
<ul>
<li>Patients with COPD frequently experience <strong>recurrent
exacerbations</strong>.</li>
<li>The goal of the trial was to determine whether a <strong>combination
treatment</strong> could reduce the rate of exacerbations compared to
monotherapy.</li>
<li>The analysis focuses on <strong>count data</strong> over a
<strong>fixed follow-up period</strong> (1 year), making <strong>rate
modeling</strong> with <strong>overdispersion</strong> appropriate.</li>
</ul>
<p><strong>Design Assumptions and Statistical Parameters</strong></p>
<table>
<thead>
<tr class="header">
<th><strong>Parameter</strong></th>
<th><strong>Value</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Significance Level (Two-Sided)</td>
<td>0.05</td>
</tr>
<tr class="even">
<td>Control Incidence Rate (per year)</td>
<td>1.4 events per subject</td>
</tr>
<tr class="odd">
<td>Rate Ratio (Treatment vs. Control)</td>
<td>0.75</td>
</tr>
<tr class="even">
<td>Exposure Time</td>
<td>1 year</td>
</tr>
<tr class="odd">
<td>Dispersion Parameter</td>
<td>0.7</td>
</tr>
<tr class="even">
<td>Power</td>
<td>90%</td>
</tr>
<tr class="odd">
<td><strong>Sample Size per Group</strong></td>
<td><strong>390 subjects</strong></td>
</tr>
</tbody>
</table>
<p><strong>Interpretation of Assumptions</strong></p>
<ul>
<li><strong>Control Rate = 1.4</strong>: On average, patients in the
control group are expected to have 1.4 exacerbations per year.</li>
<li><strong>Rate Ratio = 0.75</strong>: The treatment group is expected
to reduce exacerbation frequency by <strong>25%</strong> relative to the
control.</li>
<li><strong>Dispersion Parameter = 0.7</strong>: Accounts for
<strong>overdispersion</strong>, i.e., variability in exacerbation
counts that exceeds the Poisson assumption (where variance equals the
mean).</li>
<li><strong>Power = 90%</strong>: The study is designed to have a 90%
chance of detecting the treatment effect, assuming it exists.</li>
<li><strong>α = 0.05</strong>: A standard two-sided test with a 5%
probability of Type I error.</li>
</ul>
<p><strong>Sample Size Calculation</strong></p>
<p>The formula for Negative Binomial sample size—such as those proposed
by Zhu &amp; Lakkis (2014) or Tang (2015)—takes into account:</p>
<ul>
<li>Baseline incidence rate (λ₀)</li>
<li>Relative rate or rate ratio (RR)</li>
<li>Follow-up duration</li>
<li>Overdispersion (ϕ)</li>
<li>Desired power and significance level</li>
</ul>
<p>Using these inputs, the researchers calculated that <strong>390
subjects per group</strong> would be sufficient to detect the expected
treatment effect under these conditions.</p>
</div>
</div>
</div>
<div id="group-sequential-design-for-counts-rates"
class="section level1" number="3">
<h1><span class="header-section-number">3</span> Group Sequential Design
for Counts &amp; Rates</h1>
<p><strong>Group Sequential Design (GSD) Considerations for Counts and
Rates</strong></p>
<p>Group Sequential Designs (GSDs) allow for <strong>interim
analyses</strong> during a clinical trial, enabling early stopping for
efficacy, futility, or safety. While GSDs are well-established for
simple endpoints like means or proportions, applying them to
<strong>rates and counts</strong>, particularly for recurrent event
models (e.g., Poisson or Negative Binomial), presents new challenges and
recent developments.</p>
<p><strong>Recent Developments in GSD for Poisson and Negative Binomial
Models</strong></p>
<p>GSD methods have only recently been tailored for recurrent event
models:</p>
<ul>
<li><strong>Poisson</strong>: Standard tools are available using
<strong>normal approximations</strong>. These allow straightforward GSD
implementation based on approximated distributions of test
statistics.</li>
<li><strong>Negative Binomial (NB)</strong>: More complex, because:
<ul>
<li>There is <strong>no closed-form expression</strong> for the test
statistic’s distribution.</li>
<li>Maximum likelihood estimation (MLE) for the NB model depends on:
<ul>
<li><strong>Per-subject follow-up time</strong></li>
<li><strong>Estimated event rates</strong></li>
<li><strong>Estimated dispersion (overdispersion
parameter)</strong></li>
</ul></li>
</ul></li>
</ul>
<p>As a result, estimating the “maximum information” (a measure of total
statistical information needed to make a final decision) is <strong>much
harder</strong> in the NB case.</p>
<hr />
<p><strong>Interim Analysis Timing: A Key Open Question</strong></p>
<p>The <strong>timing of interim analyses</strong> is critical in any
GSD framework and is particularly complex in recurrent event trials:</p>
<ul>
<li><strong>For Poisson Models</strong>:
<ul>
<li>Interim looks can be scheduled based on:
<ul>
<li>A fixed <strong>percentage of total planned follow-up time</strong>,
or</li>
<li>A fixed <strong>percentage of accrued total events</strong>
(event-driven design)</li>
</ul></li>
<li>These timings are relatively predictable because the Poisson process
is memoryless and has constant rates.</li>
</ul></li>
<li><strong>For Negative Binomial Models</strong>:
<ul>
<li>Much more <strong>data-dependent</strong> because of
overdispersion.</li>
<li>Interim timing must account for:
<ul>
<li>The total <strong>interim follow-up duration</strong></li>
<li><strong>Estimated event rates</strong></li>
<li><strong>Estimated dispersion</strong></li>
</ul></li>
<li>This makes precise scheduling difficult; one can only
<strong>approximate the timing</strong> before the trial begins.</li>
<li>This uncertainty poses challenges for Independent Data Monitoring
Committees (IDMCs) who rely on timely and valid interim results.</li>
</ul></li>
</ul>
</div>
<div id="reference" class="section level1" number="4">
<h1><span class="header-section-number">4</span> Reference</h1>
<div id="counts-rates-analysis" class="section level2" number="4.1">
<h2><span class="header-section-number">4.1</span> Counts &amp; Rates
Analysis</h2>
<p>Fleiss, J.L., Levin, B. and Paik, M.C., 2013. Statistical methods for
rates and proportions. John Wiley &amp; Sons.</p>
<p>McCullagh, P. and Nelder, J.A., 1989. Generalized linear models.
Chapman and Hall. London, UK.</p>
<p>Hilbe, J.M., 2014. Modeling count data. Cambridge University
Press.</p>
<p>Cook, R.J. and Lawless, J.F., 2007. The statistical analysis of
recurrent events. New York: Springer.</p>
<p>Cameron, A.C. and Trivedi, P.K., 2013. Regression analysis of count
data. Cambridge University Press.</p>
<p>Rogers J, The Analysis of Recurrent Events: A Summary of Methodology,
Presentation to Statisticians in the Pharmaceutical Industry. URL: <a
href="https://www.psiweb.org/docs/default-source/resources/psi-subgroups/scientific/2016/time-to-event-and-recurrent-event-endpoints/jrogers.pdf"
class="uri">https://www.psiweb.org/docs/default-source/resources/psi-subgroups/scientific/2016/time-to-event-and-recurrent-event-endpoints/jrogers.pdf</a></p>
<p>Rogers, J.K., Pocock, S.J., McMurray, J.J., Granger, C.B., Michelson,
E.L., Östergren, J., Pfeffer, M.A., Solomon, S.D.,</p>
<p>Swedberg, K. and Yusuf, S., 2014. Analysing recurrent
hospitalizations in heart failure: a review of statistical methodology,
with application to CHARM‐Preserved. European journal of heart failure,
16(1), pp.33-40.</p>
<p>Yadav, C.P., Sreenivas, V., Khan, M.A. and Pandey, R.M., 2018. An
overview of statistical models for recurrent events analysis: a review.
Epidemiology (Sunnyvale), 8(4), p.354.</p>
<p>Andersen, P.K. and Gill, R.D., 1982. Cox’s regression model for
counting processes: a large sample study. The annals of statistics,
pp.1100-1120.</p>
<p>Wei, L.J., Lin, D.Y. and Weissfeld, L., 1989. Regression analysis of
multivariate incomplete failure time data by modeling marginal
distributions. Journal of the American statistical association, 84(408),
pp.1065-1073.</p>
<p>Prentice, R.L., Williams, B.J. and Peterson, A.V., 1981. On the
regression analysis of multivariate failure time data. Biometrika,
68(2), pp.373-379.</p>
<p>Andersen, P.K. and Keiding, N., 2002. Multi-state models for event
history analysis. Statistical methods in medical research, 11(2),
pp.91-115.</p>
<p>Liu, L., Wolfe, R.A. and Huang, X., 2004. Shared frailty models for
recurrent events and a terminal event. Biometrics, 60(3),
pp.747-756.</p>
<p>Box‐Steffensmeier, J.M. and De Boef, S., 2006. Repeated events
survival models: the conditional frailty model. Statistics in medicine,
25(20), pp.3518-3533.</p>
<p>Rogers, J.K., Yaroshinsky, A., Pocock, S.J., Stokar, D. and Pogoda,
J., 2016. Analysis of recurrent events with an associated informative
dropout time: application of the joint frailty model. Statistics in
medicine, 35(13), pp.2195-2205.</p>
<p>Jahn-Eimermacher, A., 2008. Comparison of the Andersen–Gill model
with Poisson and negative binomial regression on recurrent event data.
Computational Statistics &amp; Data Analysis, 52(11), pp.4989-4997.</p>
<p>Keene, O.N., Jones, M.R., Lane, P.W. and Anderson, J., 2007. Analysis
of exacerbation rates in asthma and chronic obstructive pulmonary
disease: example from the TRISTAN study. Pharmaceutical Statistics: The
Journal of Applied Statistics in the Pharmaceutical Industry, 6(2),
pp.89-97.</p>
<p>Keene, O.N., Calverley, P.M.A., Jones, P.W., Vestbo, J. and Anderson,
J.A., 2008. Statistical analysis of exacerbation rates in COPD: TRISTAN
and ISOLDE revisited. European Respiratory Journal, 32(1), pp.17-24.</p>
<p>Sormani, M.P., Bruzzi, P., Miller, D.H., Gasperini, C., Barkhof, F.
and Filippi, M., 1999. Modelling MRI enhancing lesion counts in multiple
sclerosis using a negative binomial model: implications for clinical
trials. Journal of the neurological sciences, 163(1), pp.74-80.</p>
</div>
<div id="ssd-for-counts-rates" class="section level2" number="4.2">
<h2><span class="header-section-number">4.2</span> SSD for Counts &amp;
Rates</h2>
<p>Lehr, R.,1 992. Sixteen S‐squared over D‐squared: A relation for
crude sample size estimates. Statistics in medicine, 11(8),
1099-1102.</p>
<p>Signorini, D.F., 1991. Sample size for Poisson regression.
Biometrika, 78(2), pp.446-450.</p>
<p>Shieh, G., 2001. Sample size calculations for logistic and Poisson
regression models. Biometrika, 88(4), pp.1193-1199.</p>
<p>Gu, K., Ng, H. K. T., Tang, M. L., &amp; Schucany, W. R., 2008.
Testing the ratio of two poisson rates. Biometrical Journal, 50(2),
283-298.</p>
<p>Guenther, W.C., 1977. Sampling Inspection in statistical quality
control. Macmillan.</p>
<p>Zhu, H., &amp; Lakkis, H., 2014. Sample size calculation for
comparing two negative binomial rates. Statistics in medicine, 33(3),
376-387.</p>
<p>Zhu, H., 2017. Sample size calculation for comparing two poisson or
negative binomial rates in noninferiority or equivalence trials.
Statistics in Biopharmaceutical Research, 9(1), 107-115.</p>
<p>Tang, Y., 2015. Sample size estimation for negative binomial
regression comparing rates of recurrent events with unequal follow-up
time. Journal of biopharmaceutical statistics, 25(5), 1100-1113.</p>
<p>Tang, Y., 2017. Sample size for comparing negative binomial rates in
noninferiority and equivalence trials with unequal follow-up times.
Journal of biopharmaceutical statistics, 1-17</p>
<p>Tang, Y. and Fitzpatrick, R., 2019. Sample size calculation for the
Andersen‐Gill model comparing rates of recurrent events. Statistics in
Medicine, 38(24), pp.4819-4827.</p>
<p>Zhu, L., Li, Y., Tang, Y., Shen, L., Onar‐Thomas, A. and Sun, J.,
2022. Sample size calculation for recurrent event data with additive
rates models. Pharmaceutical Statistics, 21(1), pp.89-102.</p>
<p>Lui, K.J., 2016. Crossover designs: testing, estimation, and sample
size. John Wiley &amp; Sons.</p>
<p>Mai, Y. and Zhang, Z., 2016, July. Statistical power analysis for
comparing means with binary or count data based on analogous ANOVA. In
The Annual Meeting of the Psychometric Society (pp. 381-393). Springer,
Cham.</p>
<p>Dransfield, M. T., et. al. (2013). Once-daily inhaled fluticasone
furoate and vilanterol versus vilanterol only for prevention of
exacerbations of COPD: two replicate double-blind, parallel-group,
randomised controlled trials. The lancet Respiratory medicine, 1(3),
210-223.</p>
</div>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
